Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
复制标题
可溶性白细胞介素 2 受体的水平可预测接受白细胞介素 2 和淋巴因子激活杀伤细胞治疗的患者的反应。
DOI：
10.1007/bf01676713
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Wiernik,PH
中科院分区：
文献类型：
--
作者：
Paietta,E;Nelson,DL;Andersen,J;Dutcher,JP;Wiernik,PH
Soluble interleukin-2 receptor (sIL-2R) α (CD25) levels were serially determined in the sera of 20 patients who had undergone adoptive immunotherapy with high-dose IL-2 and lymphokine-activated killer (LAK) cells for various types of metastatic solid tumors or Hodgkin’s disease. The treatment course consisted of 5 days of high-dose IL-2 priming followed by the collection of peripheral blood leukocytes by leukapheresis, andin vitroactivation of mononuclear cells with IL-2, and the subsequent infusion of such prepared LAK-cells together with IL-2. sIL-2R levels increased in all patients following IL-2 administration, and the ratio of baseline sIL-2R levels to those measured after 5 days of IL-2 was signifıcantly correlated with pre-IL-2 levels (p=0.016) in that higher pre-IL-2 levels resulted in a larger increase upon IL-2 administration. In terms of treatment outcome, the variables analysed included sIL-2R levels, total IL-2 doses administered, the expression of membrane-bound CD25 onin vitrocultured cells (pre- and post-IL-2 exposure), the total number of LAK-cells infused andin vitrocytotoxic activity of LAK-cells against the natural killer cell-resistant cell line Daudi. In a multivariate analysis, low baseline sIL-2R levels (p=0.095) and highin vitrocytotoxic activity of LAK-cells against Daudi cells (p=0.082) were jointly associated with response. Our data suggest that serum sIL-2R levels provide a fast and non-invasive parameter for predicting the response in patients treated with IL-2 and LAK-cells.
